Zogenix, Inc. (ZGNX) CEO Stephen J. Farr Sells 90,313 Shares of Stock

Zogenix, Inc. (NASDAQ:ZGNX) CEO Stephen J. Farr sold 90,313 shares of the company’s stock in a transaction on Thursday, January 10th. The shares were sold at an average price of $45.00, for a total value of $4,064,085.00. Following the completion of the sale, the chief executive officer now owns 52,259 shares of the company’s stock, valued at $2,351,655. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

ZGNX opened at $44.46 on Friday. Zogenix, Inc. has a 12-month low of $33.43 and a 12-month high of $62.75. The stock has a market cap of $1.86 billion, a P/E ratio of -11.06 and a beta of 1.79.

Zogenix (NASDAQ:ZGNX) last posted its earnings results on Thursday, November 8th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.88) by ($0.20). During the same period in the previous year, the business earned ($1.68) earnings per share. Analysts forecast that Zogenix, Inc. will post -3.84 earnings per share for the current year.



Several equities analysts have recently commented on ZGNX shares. Bank of America started coverage on Zogenix in a research note on Friday, September 14th. They issued a “buy” rating and a $63.00 price target on the stock. Zacks Investment Research lowered Zogenix from a “buy” rating to a “hold” rating in a research note on Saturday, November 17th. BidaskClub raised Zogenix from a “hold” rating to a “buy” rating in a research note on Wednesday. Leerink Swann set a $93.00 price target on Zogenix and gave the company a “buy” rating in a research note on Saturday, October 6th. Finally, Mizuho reaffirmed a “buy” rating and issued a $69.00 price target on shares of Zogenix in a research note on Thursday, December 6th. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $70.00.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Scopia Capital Management LP lifted its stake in Zogenix by 51.3% during the 3rd quarter. Scopia Capital Management LP now owns 5,306,514 shares of the company’s stock worth $263,203,000 after acquiring an additional 1,798,786 shares in the last quarter. BlackRock Inc. raised its position in Zogenix by 22.6% in the 3rd quarter. BlackRock Inc. now owns 3,604,224 shares of the company’s stock valued at $178,771,000 after purchasing an additional 664,681 shares in the last quarter. Bank of New York Mellon Corp raised its position in Zogenix by 65.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,546,543 shares of the company’s stock valued at $126,308,000 after purchasing an additional 1,011,898 shares in the last quarter. Vanguard Group Inc. raised its position in Zogenix by 18.1% in the 3rd quarter. Vanguard Group Inc. now owns 2,070,386 shares of the company’s stock valued at $102,691,000 after purchasing an additional 318,010 shares in the last quarter. Finally, Vanguard Group Inc raised its position in Zogenix by 18.1% in the 3rd quarter. Vanguard Group Inc now owns 2,070,386 shares of the company’s stock valued at $102,691,000 after purchasing an additional 318,010 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This news story was published by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://dakotafinancialnews.com/2019/01/12/zogenix-inc-zgnx-ceo-stephen-j-farr-sells-90313-shares-of-stock.html.

About Zogenix

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Read More: Debt-To-Equity Ratio

Insider Buying and Selling by Quarter for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply